Gland Pharma Limited

NSE GLAND.NS

Gland Pharma Limited Return on Equity (ROE) for the year ending March 31, 2024: 8.85%

Gland Pharma Limited Return on Equity (ROE) is 8.85% for the year ending March 31, 2024, a -9.77% change year over year. Return on equity measures profit against shareholder equity; higher ROE indicates superior profitability and value creation.

Gland Pharma Limited Return on Equity (ROE) for the year ending March 31, 2023 was 9.81%, a -42.03% change year over year.
Gland Pharma Limited Return on Equity (ROE) for the year ending March 31, 2022 was 16.93%, a 0.24% change year over year.
Gland Pharma Limited Return on Equity (ROE) for the year ending March 31, 2021 was 16.89%, a -20.32% change year over year.
Gland Pharma Limited Return on Equity (ROE) for the year ending March 31, 2020 was 21.20%, a 34.25% change year over year.

Key data

Date	Return on Equity (ROE)	Return on Capital Employed (ROCE)	Interest Coverage Ratio	Debt to Equity Ratio

NSE: GLAND.NS

Gland Pharma Limited

CEO	Mr. Shyamakant Giri
IPO Date	Nov. 20, 2020
Location	India
Headquarters	Plot No. 11 & 84, TSIIC Phase: IV
Employees	4,217
Sector	Healthcare
Industries Pharmaceuticals Clinical Trials Drugstores & Retail Pharmacies Fertilizers Telehealth

Description

Gland Pharma Limited engages in the development, manufacture, and marketing of injectable-focused generic liquid parenteral products. The company's primary molecules include heparin sodium, enoxaparin sodium, rocuronium bromide, and daptomycin injections, as well as others. It offers its products under various therapeutic categories, such as anti-infectives, anesthetics, anti-coagulants and their antidotes, anti-malarial, cardiology, gastro-intestinal, pain management, hormones and related drugs, fertility supplements, Gnrh agonists and antagonists, anti-neoplastic, gynecological, neurological and central nervous system, respiratory, blood related, ophthalmological and otological, pain/analgesics, orthopedics, hematinic, vitamins/minerals/nutrients, and others. The company also provides contract development services. It sells its products primarily under a business to business in the United States, Europe, Canada, Australia, India, and internationally. The company was incorporated in 1978 and is based in Hyderabad, India. Gland Pharma Limited is a subsidiary of Fosun Pharma Industrial Pte. Ltd.

Key trends

Past 5 years